Idalopirdine

Idalopirdine (INN; development code Lu AE58054) is a potent and selective 5-HT₆ receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer's disease and schizophrenia.^[1][2] As of October 2013 it is in phase III clinical trials.^[2]

Other namesLu-AE-58054

ATC code

• None

CAS Number

• 467459-31-0 ^N

PubChem CID

• 21071390

Quick facts Clinical data, Other names ...

Idalopirdine

Clinical data
Other names	Lu-AE-58054
ATC code	None
Identifiers
IUPAC name 2-(6-Fluoro-1H-indol-3-yl)-N-(3-(2,2,3,3-tetrafluoropropoxy)benzyl)ethanamine
CAS Number	467459-31-0 N
PubChem CID	21071390
ChemSpider	19878969 N
UNII	59WCJ0YNWM
KEGG	D10710 Y
ChEMBL	ChEMBL3286580
CompTox Dashboard (EPA)	DTXSID201026015
ECHA InfoCard	100.245.270
Chemical and physical data
Formula	C20H19F5N2O
Molar mass	398.377 g·mol−1
3D model (JSmol)	Interactive image
SMILES FC(F)C(F)(F)COc1cccc(c1)CNCCc3c[nH]c2cc(F)ccc23
InChI InChI=1S/C20H19F5N2O/c21-15-4-5-17-14(11-27-18(17)9-15)6-7-26-10-13-2-1-3-16(8-13)28-12-20(24,25)19(22)23/h1-5,8-9,11,19,26-27H,6-7,10,12H2 N Key:YBAWYTYNMZWMMJ-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Close

A phase III trial of two different daily doses of Lu AE58054 on top of 10 mg of donepezil for mild-to-moderate Alzheimer's failed to meet its primary endpoint with either dose.^[3] Two further phase III trials failed too, the company confirmed in early 2017.^[3]